(Q44759033)

6 December 2017

title

Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy (English)

1 reference

6 December 2017

0 references

1 reference

S Sarma

1

1 reference

6 December 2017

S K Fifer

series ordinal

2

1 reference

6 December 2017

publication date

1 January 1990

1 reference

6 December 2017

1 reference

6 December 2017

volume

40 Suppl 1

1 reference

6 December 2017

page(s)

42-52

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199000401-00010

6 December 2017

exact match

0 references

cites work

Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine

1 reference

12 December 2020

A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

12 December 2020

10.2165/00003495-199000401-00010

Identifiers

DOI

0 references

Dimensions Publication ID

1009772215

0 references

1 reference